NeuroPeptide Y [13-36]
-
Add time:08/22/2019 Source:sciencedirect.com
NPY [13-36] is the first agonist reported to act preferentially at NPY Y2 receptors. Subsequently, it has been demonstrated to affect several other NPY receptors. NPY [13-36] has been used experimentally to investigate various physiological effects of NPY, especially Y2-mediated actions such as transmitter release. This agent is used experimentally and has no current clinical uses.
We also recommend Trading Suppliers and Manufacturers of NEUROPEPTIDE Y (13-36) (PORCINE) (cas 113662-54-7). Pls Click Website Link as below: cas 113662-54-7 suppliers
Prev:Galanin(1-13)-Trp-32-Neuropeptide Y(25-36)Amide
Next:Research ArticleNeuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Molecular cloning, tissue distribution, and effect of fasting and refeeding on the expression of neuropeptide Y in Channa argus08/30/2019
- SERS characterization of neuropeptide Y and its C-terminal fragments deposited onto colloidal gold nanoparticle surface08/29/2019
- Neuropeptide receptors as potential pharmacological targets for obesity08/28/2019
- Pharmacological characterization of the cloned neuropeptide Y y6 receptor08/27/2019
- ReviewThe role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease☆08/26/2019
- Centrally injected neuropeptide Y (13–36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1–36) in the awake male rat08/25/2019
- Subchapter 25B - Neuropeptide Y08/24/2019
- Research ArticleNeuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain☆08/23/2019
- Galanin(1-13)-Trp-32-Neuropeptide Y(25-36)Amide08/21/2019
-
Health and Chemical more >